Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
01 Dezember 2021 - 7:30AM
Vaccines Investor Event: Sanofi reiterates confidence in strong
growth outlook and showcases pipeline of innovative vaccine
candidates
Vaccines
Investor Event:
Sanofi reiterates confidence in
strong growth outlook and showcases
pipeline of innovative vaccine candidates
- Sanofi confirms Vaccines mid-term
guidance of mid-to-high single-digit sales growth1, ambition to
more than double Vaccines sales by the end of the decade2
- Broad pipeline of innovative
vaccines, with a total of 10 candidates planned to advance into the
clinic by 2025, six of which will leverage the recently established
mRNA Center of Excellence
- Hybrid Vaccines Investor Event will
take place from 2 p.m. to 5 p.m. CET / 8 a.m. to 11 a.m. EST
(webcast, in-person meeting at Sanofi Paris Headquarters)
PARIS –
December 1, 2021 – Today, Sanofi
hosts a hybrid Vaccines Investor Event with key members of the
Vaccines leadership team to discuss how the company applies the
global Play to Win strategy to pursue growth opportunities and to
build an industry-leading vaccines pipeline.
Sanofi confirms its mid-term sales guidance
announced at the 2019 Capital Markets Day of mid-to-high
single-digit growth1 for its Vaccines business. Sustained growth
will be driven by four core franchises of influenza, meningitis,
PPH3 & Boosters, as well as the planned launch of nirsevimab, a
first-in-class monoclonal antibody for all infant protection
against Respiratory Syncytial Virus. These core franchises are well
positioned to capture market growth, such as in the global
influenza market which Sanofi expects to exceed €15 billion by
20304.
“The pandemic has elevated the crucial role of vaccines in
public health, as evidenced by the strong demand for our
differentiated flu vaccines which provide protection beyond flu by
reducing the risk of severe consequences of influenza” said Thomas
Triomphe, Executive Vice President, Sanofi Pasteur. “As a world
leader in vaccines, we are uniquely positioned to unlock the true
potential of vaccines by moving fast towards next-generation mRNA
and other technologies applicable to the prevention of disease. We
are delighted to share more details about the rapid advances of our
industry-leading vaccine programs.”
Sanofi has made significant progress in the
field of mRNA technology with the recently established Center of
Excellence and the integration of Translate Bio. Results from a
first influenza mRNA clinical trial will be shared as well as
initial successes in mRNA technology improvements. Of the 10 new
vaccine candidates planned to enter the clinic by 2025, six will
use mRNA technologies to target diseases with high unmet needs and
disease burden such as chlamydia and acne.
“Sanofi owns multiple vaccine platforms
including mRNA and builds on years of experience in the science of
immunology, structural biology, and machine learning-based antigen
design. Equipped with this set of expertise, we are best positioned
to deliver innovative vaccines designed to combat endemic and
epidemic infectious diseases. I am excited to share that Sanofi is
also opening a new chapter of its history by pioneering the use of
vaccines to tackle chronic diseases like acne,” said Jean-François
Toussaint, Head of Vaccines R&D.
Sanofi will present the following assets in its
growing R&D pipeline:
- A pneumococcal vaccine
candidate covering 21 serotypes, with Phase 1/2 clinical
trials underway in three target populations; results are expected
by end of 2022.
- A
combination of MenQuadfi
and a new meningitis B vaccine candidate to create
a best-in-class pentavalent meningococcal vaccine with broader
strain coverage; Phase 2 meningitis B read-out is expected by H2
2022 and the initiation of a Phase 1 trial for the pentavalent
candidate is planned in 2023.
- RSV
vaccine candidates for
toddlers and older
adults to address a high unmet disease
burden; Phase 1/2 trial results in toddlers are
anticipated in 2022; in parallel, an mRNA vaccine candidate for
older adults is planned to enter a Phase 1/2 study in H2 2022.
- Next
generation influenza
programs to deliver differentiated flu
vaccines that set a new standard of care; the influenza mRNA QIV
program will enter Phase 1/2 trial in 2022 and a Phase 3 trial is
planned to start in 2023; Sanofi also deploys
proprietary machine-learning to explore the potential for
better strain selection in the future.
-
Opening
new growth areas:
- Chlamydia: Sanofi
has initiated a program to prevent chlamydia infection, a silent
cause of infertility in women; a Phase 1 trial of an mRNA-based
candidate is planned to start in 2023.
- Acne: Sanofi
strives to leverage its vaccine technology to develop the first
immunotherapy against acne and to enter the clinic in 2023.
Vaccines Investor
Event detailsFor background slides and
webcast, please refer to the following
link:https://www.sanofi.com/en/investors/financial-results-and-events/investor-presentations/Vaccines-Day-2021
About Sanofi
Sanofi is dedicated to supporting people through
their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide
innovative treatments to fight pain and ease suffering. We stand by
the few who suffer from rare diseases and the millions with
long-term chronic conditions.With more than 100,000 people in 100
countries, Sanofi is transforming scientific innovation into
healthcare solutions around the globe.
Media Relations
ContactsSandrine GuendoulTel.: +33 (0)6 25 09 14
25Sandrine.Guendoul@sanofi.com
Sally BainTel.: +1 (617)
834-6026Sally.Bain@sanofi.com
Nicolas ObristTel.: +33 (0)6 77 21 27
55Nicolas.Obrist@sanofi.com
Victor RouaultTel.: +33 (0)6 70 93 71
40Victor.Rouault@sanofi.com
Investor Relations
Contacts ParisEva Schaefer-JansenArnaud DelepineNathalie
Pham
Investor Relations Contacts North
AmericaFelix Lauscher
Tel.: +33 (0)1 53 77 45
45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2020. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
1 Compound Annual Growth Rate from 2018 to 20252 From 20183 PPH:
Polio Pertussis Hib4 Source: Sanofi internal forecast
- 211201_Press_release_Vaccines_Day_EN
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024